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Abstract
Background: Asthma is a major cause of disability, health resource utilization and poor quality of life world-wide.
We set out to generate estimates of the global burden of asthma in adults, which may inform the development of
strategies to address this common disease.
Methods: The World Health Survey (WHS) was developed and implemented by the World Health Organization in
2002-2003. A total of 178,215 individuals from 70 countries aged 18 to 45 years responded to questions related to
asthma and related symptoms. The prevalence of asthma was based on responses to questions relating to self-
reported doctor diagnosed asthma, clinical/treated asthma, and wheezing in the last 12 months.
Results: The global prevalence rates of doctor diagnosed asthma, clinical/treated asthma and wheezing in adults
were 4.3%, 4.5%, and 8.6% respectively, and varied by as much as 21-fold amongst the 70 countries. Australia
reported the highest rate of doctor diagnosed, clinical/treated asthma, and wheezing (21.0%, 21.5%, and 27.4%).
Amongst those with clinical/treated asthma, almost 24% were current smokers, half reported wheezing, and 20%
had never been treated for asthma.
Conclusions: This study provides a global estimate of the burden of asthma in adults, and suggests that asthma
continues to be a major public health concern worldwide. The high prevalence of smoking remains a major barrier
to combating the global burden of asthma. While the highest prevalence rates were observed in resource-rich
countries, resource-poor nations were also significantly affected, posing a barrier to development as it stretches
further the demands of non-communicable diseases.
Background
Asthma is a major cause of disability, health resource utili-
zation and poor quality of life for those who are affected.
It is the most common chronic disease among children
and young adults, particularly because of its early onset
(one out of four individuals in the general population
develops asthma before the age of 40 years) [1], it accounts
for considerable healthcare costs and loss of work produc-
tivity [2]. In 2004, Masoli et al., and the Global Initiative
for Asthma (GINA) combined data from the Phase 1
International Study of Asthma and Allergies (ISAAC)
study collected in 1992-1996 and the European Commu-
nity Respiratory Health Survey (ECRHS) in 1988-1994 to
generate global estimates of asthma burden, which
suggested that asthma prevalence ranged from a low of
0.7% in Macau to 18.4% in Scotland [3-6]. This report esti-
mated that 300 million people worldwide had asthma, and
projected that this number would increase to 400 million
by 2025, as countries became more urbanized [4].
The GINA report however was at best a general esti-
mate, as the data on which it was based came from differ-
ent surveys collected between (1988 and 1996) using
different sampling methodologies and asthma definitions,
and recruited different age groups, The World Health
Survey (WHS) [7], designed and implemented by the
World Health Organization (WHO) from 2002 to 2003,
employed a standardized methodology to collect infor-
mation from which to estimate health of populations
which would allow within and between country compari-
sons. This data was intended to inform policy in a wide
range of countries from six continents around the world.
The WHS is public data available through the WHO
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upon request and has previously been used to estimate
the burden of other chronic diseases and risk factors for
these diseases [8-13]. This standardized cross-sectional
survey was implemented by 70 of the 192 WHO member
states, and constituted the largest multi-country survey
of asthma in adults to date. We used WHS data to esti-
mate and compare the global and country-specific bur-
den of asthma.
Methods
World health survey (WHS)
A stratified probability sampling design, where the sam-
pling frame covered 100% of the country’s eligible adults
≥ 18 years of age was used in each of the countries. The
sample was stratified by sex, age and urban/rural living
strata [7]. A multistage cluster design was used in all
countries except Australia, China, Comoros, Congo, Cote
d’Ivoire, Croatia, India, and Russia, where post-stratifica-
tion probability weight were not available (simple weights
were used), and Austria, Belgium, Denmark, Germany,
Guatemala, Netherlands, Slovenia, UK, and Zambia
where no probability weights were available.
Each respective Ministry of Health of the 70 member
states who elected to participate in the WHS was respon-
sible for designing the local sampling strategy and admin-
istering the standardized questionnaires. The sample size
for each participating country ranged from 1,000 to
10,000 participants; each country chose a sample size
based on their needs, amount of detail required and feasi-
bility/survey costs. Each of the survey modules were pilot
tested in 12 countries. Translated surveys were adminis-
tered by trained personnel either face-to-face or by tele-
phone (Australia, Israel, Luxembourg, and Norway),
using both paper and electronic questionnaire formats,
depending on feasibility [7]. Training courses for partici-
pating countries were run by WHO regional offices, and
quality standards set by the WHS Quality Assurance
Standards & Guidelines committee were monitored by
external peer review. A detailed country report, providing
details about the survey, is freely available on the WHS/
WHO website.
Definitions of asthma
A strict definition of asthma based solely on doctor diag-
nosis may be useful in some clinical settings in developed
countries; however, in developing countries it may vary
greatly depending on the context, availability, and access
to health care and medications. A combination of diag-
nosis and/or treatment for asthma may more accurately
classify individuals with active asthma. Since diagnosis
and the availability of treatment may be challenging in
resource-poor countries, a broader definition which
includes respiratory symptoms, in addition to diagnosis
and treatment received may yield a higher sensitivity in
identifying individuals with asthma. Therefore, in this
study, we estimated and compared the global burden of
asthma using three definitions of asthma. The first defini-
tion was doctor diagnosed asthma which is based on the
question “Have you ever been diagnosed with asthma?”
The second definition was clinical asthma which was
based on doctor diagnosed asthma and/or a positive
response in either of two questions “Have you ever been
treated for asthma“ or “Have you been taking any medi-
cations or treatment for asthma during the last 2 weeks?”
The third definition, symptoms of asthma, was based on
doctor diagnosed asthma, clinical asthma and/or a posi-
tive response to “During the last 12 months have you
experienced attacks of wheezing or whistling breath?” The
WHS survey questions were similar to those used by the
ISAAC and ECRHS surveys [3,5,6]. To avoid confusion
between asthma and Chronic Obstructive Pulmonary
Disease (a disease most prevalent amongst older adults);
we limited our study population to individuals aged 18 to
45 years.
Definition of smoking
Current smoking was defined based on a positive
response to the question “Do you currently smoke any
tobacco products such as cigarettes, cigars, or pipes?”.
Regional differences
Estimates of asthma prevalence were calculated for each
participating country as well as for each WHO region.
Six regions using the WHO definitions were included:
Africa (includes 18 countries), Americas (7), Eastern
Mediterranean (4), Europe (30), South East Asia (5), and
Western Pacific (6) [7,14].
Statistical analyses
All analyses were conducted using STATA statistical
software [15]. Country-specific prevalence estimates were
obtained by applying survey weights for complex sam-
pling designs. No weights were applied for pooled regio-
nal analyses [11,13]. Given the different age-distributions
in each of the participating countries, we age-standar-
dized the country specific prevalence estimates. However,
since the standardized estimates were similar to the
unadjusted estimates (Mean Difference: -0.04; 95% Limits
of Agreement: -0.07; 0.62), we presented the unadjusted
results.
Missing data
The risk factor module included questions related to
tobacco use and exposure to pollutants and was avail-
able for 53 countries [16]. Smoking data was missing for
Austria, Australia, Belgium, Denmark, Finland, France,
Germany, Greece, Ireland, Israel, Italy, Luxembourg,
Netherlands, Norway, Portugal, Sweden, and the United
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Kingdom. These countries account for only 9,803 of the
181,042 individuals (5.41%) who completed the survey.
Ethics
The study materials and methods were approved by the
research ethics board at the Hospital for Sick Children
(REB # 1000025091).
Results
Of the 181,042 individuals who completed the WHS, a
total of 178,215 (98.4%) adults in 70 countries responded
to the questions related to asthma diagnosis and respira-
tory symptoms. The median survey response rate at the
household level was 93.0%, whereas the median response
rate at the individual level was 99.0%. Country-specific
response rates can be found on the WHS website [16].
Overall, the question-specific response rates was high,
ranging from 73.3 to 97.7%. The lower response rates
observed for clinical asthma was due to low response
rates in the Americas (34.1%). All other regions had
response rates above 70% for clinical asthma.
Global burden of asthma
The global prevalence of doctor diagnosed asthma in
adults was estimated to be 4.3% (95% CI: 4.2; 4.4). The
prevalence of doctor diagnosed asthma varied widely
amongst the 70 participating countries, ranging from 0.2%
in China to 21.0% in Australia (Table 1 and Figure 1).
Using a less stringent definition, the global prevalence of
clinical asthma (or treated asthma) was 4.5% (95% CI: 4.4;
4.6). The prevalence of clinical asthma also varied widely
amongst the 70 participating countries, ranging from 1.0%
in Vietnam to 21.5% in Australia, representing a 21-fold
global variation (Table 1 and Figure 2). The five countries
with the highest prevalence of clinical asthma were Aus-
tralia (21.5%), Sweden (20.2%), UK (18.2%), Netherlands
(15.3%), and Brazil (13.0%). Finally, using the least strin-
gent definition, the global prevalence of wheezing was esti-
mated to be 8.6% (95% CI: 8.5; 8.7). The prevalence of
wheezing had a 15-fold variation across the world (Table 1
and Figure 2), with the highest rates observed in Australia
(27.4%), the Netherlands (22.7%), the United Kingdom
(22.6%), Brazil (22.6%), and Sweden (21.6%).
Regional differences in clinical or treated asthma
Overall
The prevalence of clinical asthma in adults did not differ
greatly between regions (Table 2). The highest prevalence
of clinical asthma was in the Western Pacific region
(6.2%) which was largely contributed by the high preva-
lence in Australia. The prevalence of clinical asthma was
similar in rural (4.86%) and urban (4.91%) residents in all
regions except the Western Pacific (p-value: 0.840). The
largest differences between rural (3.7%) and urban (5.1%)
were observed in the Americans.
Asthma symptoms Almost half (49.7%) of individuals
living with clinical asthma had experienced wheezing in
the last 12 months, the highest prevalence reported
being from South East Asia (57.9%).
Asthma treatment Almost a fifth of those with clinical
asthma had never received treatment for asthma in their
life.
Prevalence of smoking The prevalence of smoking in
the population with clinical asthma (23.3%) was not dif-
ferent from that of the overall global prevalence of
smoking (23.5%). In Europe and South East Asia, more
than one third of the population with clinical asthma
was currently smoking. There was no association
between prevalence of smoking amongst individuals
with asthma and the country level prevalence of asthma.
Discussion
Using standardized WHS data obtained from the WHO,
we estimated that the global prevalence of clinical asthma
in adults was 4.5% and varied by as much as 21-fold
amongst 70 participating countries. Amongst the popula-
tion living with clinical asthma, almost one in four was a
current smoker, one in two reported wheezing in the past
12 months, but one in five had never received asthma
treatment. The WHS is the first standardized, representa-
tive survey which included population-based data regard-
ing respiratory symptoms and treatment permitting
estimation of the global burden of asthma in adults. This
study provides the most current global estimates of the
burden of asthma and shows that asthma continues to be
a major public health problem worldwide.
We estimated the prevalence of asthma using three defi-
nitions ranging from the most stringent - self-reported
doctor diagnosis, to the most inclusive definition - self-
reported wheezing. Clinical history in combination with a
reversible airway obstruction as measured by a pulmonary
function test is the gold standard for diagnosing asthma.
However, implementing such a standard to identify indivi-
duals with asthma is impractical considering the scale of
the sample of this study, and would be extremely costly
and time consuming. Our questionnaire-based classifica-
tions offer a reasonable, feasible and practical alternative.
While the respiratory symptoms definition may overesti-
mate the global asthma prevalence, the clinical definition
likely underestimates disease burden in resource-poor
countries with inadequate access to health care facilities
and treatments. Our analyses focused mainly on the clini-
cal asthma definition, which identifies asthma burden
based on diagnosis and/or treatment. This definition likely
yields a lower false positive rate compared to a symptom-
based definition [17].
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Table 1 Region and country-specific estimates of asthma prevalence by 3 definitions
Asthma Prevalence (%)2
Region1 Country Doctor
Diagnosed Asthma
Clinical Asthma Wheezing Symptoms
Africa Burkina Faso 2.02 2.26 5.32
Chad 3.68 3.94 7.64
Comoros3 7.55 7.80 12.85
Congo3 4.65 4.79 7.93
Cote d’Iviore3 4.22 4.59 7.70
Ethiopia 2.00 2.00 5.53
Ghana 3.65 3.77 4.88
Kenya 2.86 3.12 6.22
Malawi 4.62 4.67 7.76
Mali 2.65 2.82 4.77
Mauritania 6.95 7.54 11.78
Mauritius 3.88 3.92 6.88
Namibia 3.16 3.39 8.14
Senegal 3.43 3.72 8.40
South Africa5 5.92 6.09 12.40
Swaziland5 8.74 9.69 15.37
Zambia4 2.83 2.96 6.25
Zimbabwe 2.28 2.52 5.48
Regional Sub-total 3.94 4.19 7.75
Americas Brazil 12.44 12.98 22.56
Dominican 9.63 9.97 12.39
Ecuador 2.03 2.13 3.83
Guatemala4 2.26 2.42 11.95
Mexico 2.39 2.39 3.87
Paraguay 6.08 6.40 12.74
Uruguay 8.60 9.10 12.02
Regional Sub-total 4.27 4.40 7.61
Eastern Mediterranean Morocco5 2.76 2.84 11.65
Pakistan 3.12 3.13 5.02
Tunisia 2.74 2.79 7.21
United Arab Emirates 5.30 2.79 7.21
Regional Sub-total 2.93 2.99 7.60
Europe Austria4 7.46 7.63 9.48
Belgium4 9.83 10.00 17.22
Bosnia Herzegovina5 1.30 1.41 4.01
Crotia3 4.38 4.57 8.66
Czech Republic 4.56 4.71 6.32
Denmark4 9.50 10.19 15.40
Estonia 2.00 1.99 6.94
Finland 9.39 10.24 17.19
France 10.43 10.59 15.20
Georgia 2.09 2.15 4.83
Germany4 7.58 7.55 9.25
Greece4 6.60 6.84 10.14
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Compared with the asthma estimates previously
reported (Table 3), our asthma estimates are more up-
to-date, are based on consistent data contributed by a
large number of developing countries, and include esti-
mates for both rural and urban dwellers. Country and
regional differences highlight the need for locally tai-
lored interventions and initiatives to address the specific
risk factors and needs. While not directly comparable
due to differences in methods used, our country-specific
estimates are broadly similar to those presented in the
GINA report [4]. We also observed that the prevalence
of asthma varied greatly between countries, with the
highest prevalence observed in resource-rich countries
[4,6]. The ISAAC study also employed a standardized
global survey and was implemented locally, but the tar-
get population was children only. Unlike the WHS,
some countries in the ISAAC study used convenience
samples and were not necessarily multi-staged or strati-
fied to be representative of the entire country. The
ISAAC study used a video questionnaire to help reduce
Table 1 Region and country-specific estimates of asthma prevalence by 3 definitions (Continued)
Hungary 7.66 7.66 14.72
Ireland 9.41 9.19 11.39
Israel 7.59 8.54 14.98
Italy4 6.05 6.26 8.98
Kazakhstan 1.43 1.47 3.36
Latvia 2.70 2.70 5.90
Luxembourg 9.16 9.44 16.63
Netherlands4 15.17 15.32 22.71
Norway 11.05 12.32 15.05
Portugal 7.83 7.83 8.72
Russia3 2.50 2.57 4.98
Slovakia 4.11 4.10 7.41
Slovenia4 8.70 8.66 11.91
Spain5 6.79 7.12 12.78
Sweden 20.09 20.18 21.60
Turkey 2.06 2.11 11.34
UK4 17.59 18.15 22.59
Ukraine 2.77 2.90 11.13
Regional Sub-total 5.1 5.28 10.71
South East Asia Bangladesh 2.91 3.23 8.63
India3 3.16 3.30 9.63
Myanmar 2.36 2.41 3.47
Nepal 2.04 2.16 14.37
Sri Lanka 2.60 2.75 6.35
Regional Sub-total 3.24 3.39 9.71
Western Pacific Australia3 20.96 21.51 27.39
China3 0.19 1.42 1.73
Laos 2.72 3.02 5.16
Malaysia 5.21 5.51 7.55
Philippines 7.21 7.46 11.01
Vietnam 0.82 1.04 2.05
Regional Sub-total 5.85 6.17 8.88
Worldwide
(95%CI)
4.27
(4.17; 4.36)
4.46
(4.36; 4.55)
8.61
(8.48; 8.74)
1 World Health Organization definition of regions
2 All asthma prevalence estimates were calculated using post satisfaction weights unless otherwise indicated
3 Post stratification weights were not available from these countries, so sampling weights were used in calculating the prevalence estimates
4 Weights were not provided these countries
5 Standard errors were missing due to a sampling unit
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misclassification due to translation of wheezing symp-
toms; this, however, was not practical for the WHS. The
ECRHS was limited to developed countries, and there-
fore cannot be used to infer global figures. Finally, since
the GINA Burden of Asthma 2004 estimates were a ret-
rospective combination of the ISAAC and ECHRS sur-
veys, the country specific estimates are not necessarily
representative of the entire population, and the
 
 
 
 
 
 
  
 
 
 0 - 2.5%
> 2.5% - 5.0% 
> 5.0% - 7.5%
> 7.5% - 10.0%
> 10.0%
No standardized data available
Figure 1 Worldwide prevalence of clinical asthma.
0 - 10.0%
> 10.0% - 15.0%
> 15.0% - 20.0%
> 20.0% - 25.0%
> 25.0%
No standardized data available
Figure 2 Worldwide prevalence of wheezing asthma.
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averaging to different surveys from the same country
introduces bias since different instruments were used.
In 2010, Sembajwe et al. used the WHS data, and
reported variations in wheezing symptoms and doctor
diagnosed asthma prevalence across world regions relating
them to national income [13]. All subjects aged 18 to 99
years from 64 countries were included in their study. They
reported a 6% prevalence of doctor diagnosed asthma and
9.2% for current wheezing, which does not agree with our
findings. The major differences between their findings and
ours may be attributed to differences in study population
included (ours included all 70 participating countries but
limited it to participants aged 18 to 45 years old). Since
our prevalence estimates were lower, it suggests that their
estimates may have been biased by the inclusion of sub-
jects with COPD as asthma.
Using the WHS data to measure the global burden
of asthma offers several strengths. Firstly, the same
standardized questionnaires were applied to all individuals
who participated. Secondly, the survey was administered
using multi-staged random sampling in most of the sites
making the country-specific estimates representative of the
whole population. The survey in each country was also
stratified by age, sex and rural/urban residence, further
improving the generalizability of our findings. Nevertheless,
the WHS data only included adults, and likely underesti-
mates the global burden, since asthma is more prevalent in
children. Canada and the United States are notable
absences from the Survey, however participation was
voluntary and these countries elected not to take part.
Therefore, our estimates likely underestimate the total glo-
bal burden of asthma, but the sample of countries included
in the WHS is sufficient to make statistically sound global
inferences
Our results highlight that asthma continues to be a
major public health concern worldwide. Applying our
Table 2 Prevalence of clinical asthma, current smoking, symptoms and treatment by regions
% Among Clinical Asthma Population Reported Symptoms in Last 12
Months
Country Regions Prevalence (%)
of Clinical Asthma
% Current Smokers % Current Smokers Asthma Ever Treated % Wheezing
Africa 4.19 12.65 13.13 78.85 53.20
Americas 4.40 22.20 23.28 82.62 38.12
Eastern Mediterranean 2.99 19.41 17.52 85.52 54.45
Europe 5.28 39.25 35.85 90.24 49.64
South East Asia 3.39 30.23 34.11 78.00 57.86
Western Pacific 6.17 31.46 28.38 77.11 50.84
Global 4.46 23.46 23.33 81.91 49.69
Table 3 Summary of prevalence of asthma reported in the literature
Authors Data
Collection
Period
Study &
Survey
Used
Definitions of Asthma Sample
Size
Countries
Included
Age
Groups
Findings of Asthma Prevalence
ECRHS (1996)5 1988-1994 ECRHS An asthma attack in the last
12 months or currently
taking asthma medication
137,619 12 20-44 Ranged from 2.0% in Estonia to 11.9% in
Australia with a median of 4.5%
ISAAC Steering
Committee
(1998)3
1992-1996 ISAAC
Phase 1
Self-reported ever had
asthma
721,601 56 6-7 and
13-14
11.3% in children aged 13 14 years and
10.2% in children aged 6-7 years
ISAAC Steering
Committee
(1998)6
1992-1996 ISAAC
Phase 1
Wheezing or whistling in
the chest in the last 12
months
463,801 55 13-14 Ranged from 1.6% in Indonesia to 36.8%
in the UK
Masoli et al.
(2004)4
1988-1996 ISAAC and
ECRHS
Various depending on the
survey and country
Not
reported
76 13-14
and 20-
44
Ranged from 0.7% in Macau to 18.4% in
Scotland
Lai et al. (2009)18 2000-2003 ISAAC
Phase 3
Wheeze in the past 12
months
1,187,496 98 6-7 and
13-14
14.1% in children 13-14 years and 11.5%
in children 6-7 years
Sembajwe et al.
(2010)13
2002-2003 WHS Doctor diagnosis 308,218 64 18-99 Ranged from 1.8% in Vietnam to 32.8%
in Australia with an overall 6.0%
To et al. (2011)
(Current study)
2002-2003 WHS Doctor diagnosis, clinical
and symptoms of asthma
177,496 70 18-45 4.3% doctor diagnosed asthma, 4.5%
clinical asthma and 14.4% symptoms of
asthma
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4.5% clinical asthma prevalence to the current world
population of 7 billion translates to 315 million indivi-
duals with asthma. However, using our 8.6% self-reported
prevalence of asthma symptoms, we estimated that nearly
623 million individuals are currently living with some
level of asthma-related symptoms worldwide. While
proper long-term management of asthma will allow indi-
viduals with asthma to achieve good levels of control
enabling them to live with good quality of life, our data
indicates that asthma control is not optimal in many
countries. Worldwide, nearly half of the asthma popula-
tion reported wheezing in the last 12 months, and only a
moderate proportion had been diagnosed and/or received
treatment. In addition, the high prevalence of smoking
continues to be one of the major barriers in combating
the global burden of asthma. While the highest overall
prevalence of asthma was observed in resource-rich
countries, many resource-poor nations also have a high
prevalence of this disease. This is of concern because in
most such countries, resources are consumed by the
pressing demands of infectious diseases and the need to
provide primary care for the broader population. In many
countries there is little, if any provision of the essential
medications that at both individual and population level
can lead to very satisfactory control of asthma. Uncon-
trolled asthma poses an extra weight in the burden of
non-communicable disease, which constitutes a major
barrier for development.
Conclusions
The asthma statistics from the WHS presented here may
be useful to health policy and decision makers, clinicians,
and researchers in designing programs and plans of
action to address risk factors such as smoking and
improve quality of provided for asthma and reduce the
burden that it presents, through provision of treatment
that is adequate, accessible, and effective.
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